Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy MorphoSys stock | $11.47

Learn how to easily invest in MorphoSys stock.

MorphoSys AG is a biotechnology business based in the US. MorphoSys shares (MOR) are listed on the NASDAQ and all prices are listed in US Dollars. MorphoSys employs 607 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in MorphoSys

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MOR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

MorphoSys stock price (NASDAQ: MOR)

Use our graph to track the performance of MOR stocks over time.

MorphoSys shares at a glance

Information last updated 2021-10-24.
Latest market close$11.47
52-week range$10.86 - $30.75
50-day moving average $12.02
200-day moving average $17.09
Wall St. target price$24.95
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.91

Buy MorphoSys shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy MorphoSys stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

MorphoSys price performance over time

Historical closes compared with the close of $11.47 from 2021-10-25

1 week (2021-10-19) 0.70%
1 month (2021-09-24) -5.83%
3 months (2021-07-26) -22.76%
6 months (2021-04-26) -51.36%
1 year (2020-10-26) -54.90%
2 years (2019-10-25) -59.20%
3 years (2018-10-26) 22
5 years (2016-10-22) N/A

Is MorphoSys under- or over-valued?

Valuing MorphoSys stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of MorphoSys's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

MorphoSys's EBITDA

MorphoSys's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $38.7 million.

The EBITDA is a measure of a MorphoSys's overall financial performance and is widely used to measure a its profitability.

MorphoSys financials

Revenue TTM $143.5 million
Gross profit TTM $318.5 million
Return on assets TTM -9.04%
Return on equity TTM -16.31%
Profit margin -71.5%
Book value $4.59
Market capitalisation $1.5 billion

TTM: trailing 12 months

Shorting MorphoSys shares

There are currently 117,181 MorphoSys shares held short by investors – that's known as MorphoSys's "short interest". This figure is 15.6% down from 138,819 last month.

There are a few different ways that this level of interest in shorting MorphoSys shares can be evaluated.

MorphoSys's "short interest ratio" (SIR)

MorphoSys's "short interest ratio" (SIR) is the quantity of MorphoSys shares currently shorted divided by the average quantity of MorphoSys shares traded daily (recently around 63341.081081081). MorphoSys's SIR currently stands at 1.85. In other words for every 100,000 MorphoSys shares traded daily on the market, roughly 1850 shares are currently held short.

However MorphoSys's short interest can also be evaluated against the total number of MorphoSys shares, or, against the total number of tradable MorphoSys shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case MorphoSys's short interest could be expressed as 0% of the outstanding shares (for every 100,000 MorphoSys shares in existence, roughly 0 shares are currently held short) or 0.0009% of the tradable shares (for every 100,000 tradable MorphoSys shares, roughly 1 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against MorphoSys.

Find out more about how you can short MorphoSys stock.

MorphoSys share dividends

We're not expecting MorphoSys to pay a dividend over the next 12 months.

MorphoSys share price volatility

Over the last 12 months, MorphoSys's shares have ranged in value from as little as $10.86 up to $30.75. A popular way to gauge a stock's volatility is its "beta".

MOR.US volatility(beta: 0.77)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MorphoSys's is 0.7732. This would suggest that MorphoSys's shares are less volatile than average (for this exchange).

MorphoSys overview

MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; and MOR106, an antibody for atopic dermatitis. It also develops Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Frequently asked questions

What percentage of MorphoSys is owned by institutions?
Currently 1.818% of MorphoSys shares are held by institutions.
How many people work for MorphoSys?
Latest data suggests 607 work at MorphoSys.
When does the fiscal year end for MorphoSys?
MorphoSys's fiscal year ends in December.
Where is MorphoSys based?
MorphoSys's address is: Semmelweisstrasse 7, Planegg, Germany, 82152
What is MorphoSys's ISIN number?
MorphoSys's international securities identification number is: US6177602025
What is MorphoSys's CUSIP number?
MorphoSys's Committee on Uniform Securities Identification Procedures number is: 617760202

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site